95-20460. Advisory Committee; Notice of Meeting  

  • [Federal Register Volume 60, Number 160 (Friday, August 18, 1995)]
    [Notices]
    [Pages 43158-43160]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 95-20460]
    
    
    
    -----------------------------------------------------------------------
    
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Advisory Committee; Notice of Meeting
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: This notice announces a forthcoming meeting of a public 
    advisory committee of the Food and Drug Administration (FDA). This 
    notice also summarizes the procedures for the meeting and methods by 
    which interested persons may participate in open public hearings before 
    FDA's advisory committees.
    
        FDA has established an Advisory Committee Information Hotline (the 
    hotline) using a voice-mail telephone system. The hotline provides the 
    public with access to the most current information on FDA advisory 
    committee meetings. The advisory committee hotline, which will 
    disseminate current information and information updates, 
    
    [[Page 43159]]
    can be accessed by dialing 1-800-741-8138 or 301-443-0572. Each 
    advisory committee is assigned a 5-digit number. This 5-digit number 
    will appear in each individual notice of meeting. The hotline will 
    enable the public to obtain information about a particular advisory 
    committee by using the committee's 5-digit number. Information in the 
    hotline is preliminary and may change before a meeting is actually 
    held. The hotline will be updated when such changes are made.
    MEETING: The following advisory committee meeting is announced:
    Anesthesiology and Respiratory Therapy Devices Panel of the Medical 
    Devices Advisory Committee
        Date, time, and place. September 8, 1995, 8 a.m., Corporate Bldg., 
    rm. 20B, 9200 Corporate Blvd., Rockville, MD. A limited number of 
    overnight accommodations have been reserved at the Marriott 
    Washingtonian Hotel, 9751 Washingtonian Blvd., Gaithersburg, MD. 
    Attendees requiring overnight accommodations may contact the hotel at 
    301-590-0044 and reference the FDA Panel meeting block. Reservations 
    will be confirmed at the group rate based on availability. Attendees 
    with a disability requiring special accommodations should contact Ed 
    Rugenstein, Sociometrics, Inc., 301-608-2151. The availability of 
    appropriate accommodations cannot be assured unless prior written 
    notification is received.
        Type of meeting and contact person. Closed committee deliberations, 
    8 a.m. to 9 a.m.; open public hearing, 9 a.m. to 11 a.m., unless public 
    participation does not last that long; open committee discussion, 11 
    a.m. to 4:30 p.m.; Michael Bazaral, Center for Devices and Radiological 
    Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., 
    Rockville, MD 20850, 301-443-8609, or the FDA Advisory Committee 
    Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC 
    area), Anesthesiology and Respiratory Therapy Devices Panel, code 
    12624.
        General function of the committee. The committee reviews and 
    evaluates data on the safety and effectiveness of marketed and 
    investigational devices and makes recommendations for their regulation.
        Agenda--Open public hearing. Interested persons may present data, 
    information, or views, orally or in writing, on issues pending before 
    the committee. Those desiring to make formal presentations should 
    notify the contact person before August 29, 1995, and submit a brief 
    statement of the general nature of the evidence or arguments they wish 
    to present, the names and addresses of proposed participants, and an 
    indication of the approximate time required to make their comments.
        Open committee discussion. The committee will hear presentations 
    and discuss a draft guidance document for data to support premarket 
    notification submissions for ventilators, including both conventional 
    positive pressure ventilators and positive pressure ventilators which 
    function using a continually open exhalation port associated with the 
    patient mask or other patient connection.
        Single copies of the draft guidance document are available from the 
    contact person for this meeting. Copies may also be obtained through 
    the Division of Small Manufacturer's Assistance; requests should 
    reference document 500. For delivery by mail, fax requests to Les Grams 
    at 301-443-8818 (include mailing address). Copies are available from 
    Facts on Demand (1-800-899-0311) and are available from the Electronic 
    Docket via terminal or personal computer (1-800-252-1366); to receive 
    detailed instructions for requesting electronic transmission (including 
    fax), fax a request for !BP__DSMA.FAX to Geoffrey Clark at 301-443-
    8818.
        Closed committee deliberations. FDA staff will present to the 
    committee trade secret and/or confidential commercial information 
    regarding present and future FDA issues. This portion of the meeting 
    will be closed to permit discussion of this information (5 U.S.C. 
    552b(c)(4)).
        Each public advisory committee meeting listed above may have as 
    many as four separable portions: (1) An open public hearing, (2) an 
    open committee discussion, (3) a closed presentation of data, and (4) a 
    closed committee deliberation. Every advisory committee meeting shall 
    have an open public hearing portion. Whether or not it also includes 
    any of the other three portions will depend upon the specific meeting 
    involved. The dates and times reserved for the separate portions of 
    each committee meeting are listed above.
        The open public hearing portion of each meeting shall be at least 1 
    hour long unless public participation does not last that long. It is 
    emphasized, however, that the 1 hour time limit for an open public 
    hearing represents a minimum rather than a maximum time for public 
    participation, and an open public hearing may last for whatever longer 
    period the committee chairperson determines will facilitate the 
    committee's work.
        Public hearings are subject to FDA's guideline (subpart C of 21 CFR 
    part 10) concerning the policy and procedures for electronic media 
    coverage of FDA's public administrative proceedings, including hearings 
    before public advisory committees under 21 CFR part 14. Under 21 CFR 
    10.205, representatives of the electronic media may be permitted, 
    subject to certain limitations, to videotape, film, or otherwise record 
    FDA's public administrative proceedings, including presentations by 
    participants.
        Meetings of advisory committees shall be conducted, insofar as is 
    practical, in accordance with the agenda published in this Federal 
    Register notice. Changes in the agenda will be announced at the 
    beginning of the open portion of a meeting.
        Any interested person who wishes to be assured of the right to make 
    an oral presentation at the open public hearing portion of a meeting 
    shall inform the contact person listed above, either orally or in 
    writing, prior to the meeting. Any person attending the hearing who 
    does not in advance of the meeting request an opportunity to speak will 
    be allowed to make an oral presentation at the hearing's conclusion, if 
    time permits, at the chairperson's discretion.
        The agenda, the questions to be addressed by the committee, and a 
    current list of committee members will be available at the meeting 
    location on the day of the meeting.
        Transcripts of the open portion of the meeting may be requested in 
    writing from the Freedom of Information Office (HFI-35), Food and Drug 
    Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857, 
    approximately 15 working days after the meeting, at a cost of 10 cents 
    per page. The transcript may be viewed at the Dockets Management Branch 
    (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., 
    Rockville, MD 20857, approximately 15 working days after the meeting, 
    between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary 
    minutes of the open portion of the meeting may be requested in writing 
    from the Freedom of Information Office (address above) beginning 
    approximately 90 days after the meeting.
        The Commissioner has determined for the reasons stated that those 
    portions of the advisory committee meetings so designated in this 
    notice shall be closed. The Federal Advisory Committee Act (FACA) (5 
    U.S.C. app. 2, 10(d)), permits such closed advisory committee meetings 
    in certain circumstances. 
    
    [[Page 43160]]
    Those portions of a meeting designated as closed, however, shall be 
    closed for the shortest possible time, consistent with the intent of 
    the cited statutes.
        The FACA, as amended, provides that a portion of a meeting may be 
    closed where the matter for discussion involves a trade secret; 
    commercial or financial information that is privileged or confidential; 
    information of a personal nature, disclosure of which would be a 
    clearly unwarranted invasion of personal privacy; investigatory files 
    compiled for law enforcement purposes; information the premature 
    disclosure of which would be likely to significantly frustrate 
    implementation of a proposed agency action; and information in certain 
    other instances not generally relevant to FDA matters.
        Examples of portions of FDA advisory committee meetings that 
    ordinarily may be closed, where necessary and in accordance with FACA 
    criteria, include the review, discussion, and evaluation of drafts of 
    regulations or guidelines or similar preexisting internal agency 
    documents, but only if their premature disclosure is likely to 
    significantly frustrate implementation of proposed agency action; 
    review of trade secrets and confidential commercial or financial 
    information submitted to the agency; consideration of matters involving 
    investigatory files compiled for law enforcement purposes; and review 
    of matters, such as personnel records or individual patient records, 
    where disclosure would constitute a clearly unwarranted invasion of 
    personal privacy.
        Examples of portions of FDA advisory committee meetings that 
    ordinarily shall not be closed include the review, discussion, and 
    evaluation of general preclinical and clinical test protocols and 
    procedures for a class of drugs or devices; consideration of labeling 
    requirements for a class of marketed drugs or devices; review of data 
    and information on specific investigational or marketed drugs and 
    devices that have previously been made public; presentation of any 
    other data or information that is not exempt from public disclosure 
    pursuant to the FACA, as amended; and, deliberation to formulate advice 
    and recommendations to the agency on matters that do not independently 
    justify closing.
        This notice is issued under section 10(a)(1) and (2) of the Federal 
    Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR 
    part 14) on advisory committees.
    
        Dated: August 10, 1995.
    Linda A. Suydam,
    Interim Deputy Commissioner for Operations.
    [FR Doc. 95-20460 Filed 8-17-95; 8:45 am]
    BILLING CODE 4160-01-F
    
    

Document Information

Published:
08/18/1995
Department:
Health and Human Services Department
Entry Type:
Notice
Action:
Notice.
Document Number:
95-20460
Pages:
43158-43160 (3 pages)
PDF File:
95-20460.pdf